Skip to content

Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation

Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01184625
Enrollment
30
Registered
2010-08-19
Start date
2008-01-31
Completion date
2012-08-31
Last updated
2011-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myositis

Keywords

Myositis, Physical exercise, Disability

Brief summary

The objectives of this study are to test if hypoxia in muscle tissue is an important factor contributing to clinical symptoms in chronic rheumatic muscle inflammation and to evaluate if a 12 week endurance exercise program will improve muscle tissue hypoxia and disability in patients with chronic rheumatic muscle inflammation.

Interventions

OTHERPhysical Exercise

12 weeks of physical exercise.

Sponsors

Uppsala University Hospital
CollaboratorOTHER
Sahlgrenska University Hospital
CollaboratorOTHER
Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with chronic, stable polymyositis or dermatomyositis with diagnosis of definite or probable polymyositis or dermatomyositis (Bohan and Peter 1975) * Age 18-80 years * Duration since diagnosis \> 6 months * Exercising \< once a week, * Stable disease activity and medication for at least one month. Ten healthy controls matched for age, gender and physical exercise level will be included. \-

Exclusion criteria

* Severe pulmonary fibrosis * Heart or lung conditions that contraindicate vigorous exercise * Severe osteoporosis * Not being able to perform the exercise program.

Design outcomes

Primary

MeasureTime frame
Hypoxia related metabolites.At baseline before intervention.

Secondary

MeasureTime frame
Muscle impairment.At baseline before intervention.

Countries

Sweden

Contacts

Primary ContactIngrid E Lundberg, MD, PhD, Prof
ingrid.lundberg@ki.se+46 8 517700

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026